caa a22 4500 477054692 CHVBK 20180405111345.0 cr unu---uuuuu 170330e19960701xx s 000 0 eng 10.1007/BF02592355 doi (NATIONALLICENCE)springer-10.1007/BF02592355 Inhibition of HIV-1 infectivity by low molecular weight heparin [Elektronische Daten] Results of in vitro studies and a pilot clinical trial in patients with advanced AIDS [A. Howell, T. Taylor, J. Miller, D. Groveman, E. Eccles, L. Zacharski] Several sulfated polysaccharides have been shown to have anti-HIV activity in vitro. However, many of these compounds are not suited for use in vivo because they present an increased risk of bleeding or cannot be administered chronically. We tested the anti-HIV effects of low molecular weight heparin (LMW-heparin) (Enoxaparin) in vitro using a model system of HIV infectivity because LMW-heparin can be given to patients on a longterm basis with little risk. In vitro, LMW-heparin was shown to inhibit HIV-1 production from a T cell lymphoma line (H9) and phytohemagglutinin-stimulated lymphoblasts. Inhibition of infectivity was dose dependent at concentrations achievable in vivo. We then performed a pilot clinical trial in 13 patients with advanced AIDS of 6 months of chronic, self-administered Enoxaparin given in standard prophylactic doses. CD4 counts appeared to stabilize or increase in most patients during the first 3 months of treatment, then remained stable or declined after 6 months. There was no appreciable change in serum p24 levels. There was no evidence of drug toxicity and no bleeding episodes. These findings demonstrate that a commercially available, relatively non-toxic form of LMW-heparin is a potent inhibitor of HIV-1 production in cultured cells and that it is feasible to treat patients with AIDS with LMW-heparin on a long-term basis. Definitive clinical trials of LMW-heparins and related compounds as experimental anti-viral agents in patients with HIV infection are indicated. Springer-Verlag, 1992 Human immunodeficiency virus-1 nationallicence Acquired immunodeficiency syndrome nationallicence Heparin nationallicence Howell A. Veterans Administration Medical Center, 05009, White River Junction, VT, USA aut Taylor T. Veterans Administration Medical Center, 05009, White River Junction, VT, USA aut Miller J. Department of Microbiology, Dartmouth Medical School, Lebanon, New Hamsphire, USA aut Groveman D. Department of Microbiology, Dartmouth Medical School, Lebanon, New Hamsphire, USA aut Eccles E. Department of Medicine, Dartmouth Medical School, Lebanon, New Hampshire, USA aut Zacharski L. Veterans Administration Medical Center, 05009, White River Junction, VT, USA aut International Journal of Clinical and Laboratory Research Springer-Verlag 26/2(1996-07-01), 124-131 0940-5437 26:2<124 1996 26 599 https://doi.org/10.1007/BF02592355 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02592355 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Howell A. Veterans Administration Medical Center, 05009, White River Junction, VT, USA aut NATIONALLICENCE 700 1- Taylor T. Veterans Administration Medical Center, 05009, White River Junction, VT, USA aut NATIONALLICENCE 700 1- Miller J. Department of Microbiology, Dartmouth Medical School, Lebanon, New Hamsphire, USA aut NATIONALLICENCE 700 1- Groveman D. Department of Microbiology, Dartmouth Medical School, Lebanon, New Hamsphire, USA aut NATIONALLICENCE 700 1- Eccles E. Department of Medicine, Dartmouth Medical School, Lebanon, New Hampshire, USA aut NATIONALLICENCE 700 1- Zacharski L. Veterans Administration Medical Center, 05009, White River Junction, VT, USA aut NATIONALLICENCE 773 0- International Journal of Clinical and Laboratory Research Springer-Verlag 26/2(1996-07-01), 124-131 0940-5437 26:2<124 1996 26 599 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer